UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 2.006

Sortiert nach

Acute myeloid leukaemia in Afghanistan: Understanding an unfamiliar landscape

British journal of haematology, 2023-11, Vol.203 (3), p.353-354

Hills, Robert K.

2023

Link zum Volltext

Verfügbarkeit prüfen

What drives CAR‐T emergent cytopenia?

British journal of haematology, 2023-07, Vol.202 (2), p.213-214

Hills, Robert K.

2023

Link zum Volltext

Verfügbarkeit prüfen

Historical controls and venous thromboembolism prophylaxis in acute lymphoblastic leukaemia: things can only get better?

British journal of haematology, 2022-04, Vol.197 (2), p.e26-e27

Hills, Robert K.

2022

Link zum Volltext

Verfügbarkeit prüfen

High on‐treatment platelet reactivity—an OPTIMAl solution, or a better solution?

British journal of haematology, 2022-01, Vol.196 (2), p.272-273

Hills, Robert K.

2022

Link zum Volltext

Verfügbarkeit prüfen

Diagnosing Diamond–Blackfan anaemia: ‘Vorsprung durch Technik’

British journal of haematology, 2021-06, Vol.193 (6), p.1030-1031

Hills, Robert K.

2021

Link zum Volltext

Verfügbarkeit prüfen

Evaluating sixty years of UK trials research in acute myeloid leukaemia: lessons for trial design, past, present and future

British journal of haematology, 2020-01, Vol.188 (1), p.29-35

Hills, Robert K.

2020

Link zum Volltext

Verfügbarkeit prüfen

Arsenic trioxide and all- trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial

The lancet oncology, 2015-10, Vol.16 (13), p.1295-1305

2015

Link zum Volltext

Verfügbarkeit prüfen

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials

Blood, 2010-07, Vol.116 (3), p.354-365

2010

Link zum Volltext

Verfügbarkeit prüfen

Assessment of Minimal Residual Disease in Standard-Risk AML

The New England journal of medicine, 2016-02, Vol.374 (5), p.422-433

2016

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia

Journal of clinical oncology, 2013-11, Vol.31 (32), p.4123-4131

2013

Link zum Volltext

Verfügbarkeit prüfen

Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial

Blood, 2012-10, Vol.120 (14), p.2826-2835

2012

Link zum Volltext

Verfügbarkeit prüfen

Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial

Journal of clinical oncology, 2013-09, Vol.31 (27), p.3360-3368

2013

Link zum Volltext

Verfügbarkeit prüfen

Real world data and the art of maintenance therapy

British journal of haematology, 2019-02, Vol.184 (4), p.493-494

Hills, Robert K.

2019

Link zum Volltext

Verfügbarkeit prüfen

Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations

Journal of clinical oncology, 2018-05, Vol.36 (15), p.1486-1497

2018

Link zum Volltext

Verfügbarkeit prüfen

Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia

Journal of clinical oncology, 2012-11, Vol.30 (32), p.3924-3931

2012

Link zum Volltext

Verfügbarkeit prüfen

Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial

Journal of clinical oncology, 2011-02, Vol.29 (4), p.369-377

2011

Link zum Volltext

Verfügbarkeit prüfen

Statistical reporting in the BJH: some dos and don'ts

British journal of haematology, 2017-02, Vol.176 (3), p.345-351

Hills, Robert K.

2017

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study

The Lancet (British edition), 2007-12, Vol.370 (9604), p.2020-2029

2007

Link zum Volltext

Verfügbarkeit prüfen

Curability of Patients With Acute Myeloid Leukemia Who Did Not Undergo Transplantation in First Remission

Journal of clinical oncology, 2013-04, Vol.31 (10), p.1293-1301

2013

Link zum Volltext

Verfügbarkeit prüfen

Non‐inferiority trials: No better? No worse? No change? No pain?

British journal of haematology, 2017-03, Vol.176 (6), p.883-887

Hills, Robert K.

2017

Link zum Volltext

Verfügbarkeit prüfen

Pml nuclear body disruption cooperates in APL pathogenesis and impairs DNA damage repair pathways in mice

Blood, 2018-02, Vol.131 (6), p.636-648

2018

Link zum Volltext

Verfügbarkeit prüfen

Twenty five years of UK trials in acute myeloid leukaemia: what have we learned?

British journal of haematology, 2020-01, Vol.188 (1), p.86-100

2020

Link zum Volltext

Verfügbarkeit prüfen

Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma

Blood, 2011-05, Vol.117 (18), p.4726-4735

2011

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 2.006

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.234)
Mit Volltextzugriff
(1.747)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(979)
Humans
(770)
Life Sciences & Biomedicine
(641)
Female
(448)
Male
(421)
Middle Aged
(306)
Adult
(273)
Aged
(248)
Science & Technology - Other Topics
(216)
Multidisciplinary Sciences
(212)
Patients
(155)
Physical Sciences
(153)
Treatment Outcome
(153)
Biological And Medical Sciences
(143)
Adolescent
(138)
Clinical Trials
(138)
Social Sciences
(137)
Medical Sciences
(126)
Studies
(124)
Hematology
(122)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Plos One
(184)
Blood
(134)
British Journal Of Haematology
(46)
The New England Journal Of Medicine
(30)
Journal Of Clinical Oncology
(24)
The Lancet
(18)
Chest
(12)
Nature
(12)
Pediatrics
(11)
Journal Of Neurosurgery
(10)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Acute myeloid leukaemia in Afghanistan: Understanding an unfamiliar landscape

What drives CAR‐T emergent cytopenia?

Historical controls and venous thromboembolism prophylaxis in acute lymphoblastic leukaemia: things can only get better?

High on‐treatment platelet reactivity—an OPTIMAl solution, or a better solution?

Diagnosing Diamond–Blackfan anaemia: ‘Vorsprung durch Technik’

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

Evaluating sixty years of UK trials research in acute myeloid leukaemia: lessons for trial design, past, present and future

Arsenic trioxide and all- trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial

Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials

Assessment of Minimal Residual Disease in Standard-Risk AML

Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia

Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial

Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial

Real world data and the art of maintenance therapy

Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations

Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia

Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial

Statistical reporting in the BJH: some dos and don'ts

Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study

Curability of Patients With Acute Myeloid Leukemia Who Did Not Undergo Transplantation in First Remission

Non‐inferiority trials: No better? No worse? No change? No pain?

Pml nuclear body disruption cooperates in APL pathogenesis and impairs DNA damage repair pathways in mice

Twenty five years of UK trials in acute myeloid leukaemia: what have we learned?

Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma

Suchergebnisse filtern